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Abstract Dyspnoea remains a remarkable clinicalproblemand a therapeutic challenge, mainly in chronic respiratory
conditions.This study investigated the potential effects of steroids on dyspnoea sensation regardless of their pulmonary
anti-inflammatory actions. Sixteenhealthymen (mean age+ SD = 22.5+1.6 years) developeduncomfortable breathing
by the use of inspiratory resistors (loads of 0, 7,14 and 21cm H2O/l/s) and breathholding 6 h after taking 40mg of pre-
dnisone (Pred) or placebo (Plac).Respiratorydiscomfortduring breathingwith loadswas evaluatedwith a100mmvisual
analog scale. The maximum voluntary apnoea time did not differ between the prednisone and placebo days (Plac=
96+11.8 s Pred=105+12.2 s) andprednisone didnot influence the dyspnoea sensation inducedbydifferent inspiratory
loads (0 cm H2O/l/s: Pred=2.8mm Plac=1.9mm; 7 cm H2O/l/s: Pred=18.3mm Plac=18.6mm; 14 cm H2O/l/s;
Pred=33.0mm Plac=34.1mm; 21cmH2O/l/s:Pred=48.1mm Plac=49.6mm).Prednisone intakewas associatedwith
a significant increase in minute ventilation during breathing with no inspiratory loads (Pred=11.91+1.28 l/min-
 Plac=9.95+0.86 l/min). Although steroids certainlymay improve respiratory conditions due to anti-inflammatory ac-
tions, available evidence does not support any specific beneficial effect of these drugs on the perception of dyspnoea
itself.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1314, available online at http://www.idealibrary.comon
Keywords dyspnoea; steroids; pulmonary function; analog scale.Dyspnoea is one of themost commoncomplaints among
patients with cardiorespiratory diseases and is often the
reasonwhy a person seeksmedical care.Thepresence of
unpleasant respiratory sensations is themost important
symptom a¡ecting the quality of life in patients with
chronic respiratory failure (1,2). Althoughourknowledge
about the physiological mechanisms that generate the
respiratory sensations has increased in the past two
years, dyspnoea still remains a tremendous clinical pro-
blem and a therapeutic challenge (3). An agent able to re-
duce dyspnoea without signi¢cant side-e¡ects would
never be a substitute for speci¢c therapy directed at
the underlying respiratory disorder, but could be useful,
mainly when the condition is irreversible (4).
Steroids are chemical agents with multiple physiologi-
cal and therapeutic actions (5).Cortisol release is an im-
portant metabolic component of the ¢ght or run
response to stress conditions. In addition, we have ob-
served in our clinical practice that some patients withReceived 8 October 2001, accepted in revised form1February 2002.
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improvement of their symptoms on oral prednisone,
althoughpulmonary function parameters do not change.
Therefore, we raised the hypothesis that steroids could
have a bene¢cial e¡ect on dyspnoea sensation indepen-
dent of their well-known pulmonary anti-in£ammatory
actions.
The present study was designed to investigate the ef-
fects of oral prednisone vs placebo on respiratory sensa-
tions in a group of healthy volunteers who developed
uncomfortable breathing by the use of inspiratory resis-
tors and keeping voluntary apnoea.
MATERIALANDMETHODS
Subject
Sixteen non-smoking, healthy male volunteers partici-
pated in the study after giving informed consent. None
of the subjects had respiratory symptoms, past pulmon-
ary illnesses and all had a normal physical examination.
Special carewas taken to exclude subjectswith a history
of asthma or wheezing during childhood. Age ranged
from19 to 25 years, with amean+ SD of 22.5+1.6 years.
The study was approved by the Ethics Committee of
Hospital das Cl|¤nicas de Ribeira- o Preto.
FIG. 1. Maximum voluntary apnoea times for 16 volunteers
after takingplacebo or 40mgof prednisone.
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Study design: Dyspnoeic sensations were induced by
breathholding and breathing with di¡erent inspiratory
resistive loadings.Thevolunteers came to thepulmonary
function laboratory three times. On the ¢rst day (D-l),
they performed spirometry and dyspnoea tests in order
to familiarize themselves with the maneuvers. On the
second (D-2) and third days (D-3), they weremedicated
with placebo or with 40mg of PO prednisone 6h before
the tests. Drug or placebo was administered at random
and in a double-blind manner. All tests were performed
around midday at least 2 days apart, and with the sub-
jects breathing room air.
Spirometry: Basal pulmonary function data were ob-
tained using a Pulmonet Godard spirometer. Procedures
were performed according to American Thoracic So-
ciety recommendations (6). Forced vital capacity (FVC),
forced expiratory volume in the ¢rst second (FEVl) and
the middle curve forced expiratory £ow (FEF25^75%)
were analyzed as predicted of normal values. The FEV1/
FVC ratios were expressed as percentage values. The
predicted normal values were based on Crapo et al. (7).
Breathholding:When thevolunteers arrived at thepul-
monary function laboratory they received an explana-
tion of the proceedings and, after a brief resting period,
were asked to hold their breath at the total lung capacity
level, the most they could. An observer employed a
chronometer to measure the apnoea length, while the
volunteers used hand signaling to indicate the beginning
and the end of the breathholding period.The maximum
voluntary apnea time was measured twice, at least 15
minutes apart, and the duration was expressed as sec-
onds.The best value obtained between the twomaneu-
vers was chosen for analysis.
Breathing with inspiratory loads: Each subject breathed
through an oral one-way valve systemduring the experi-
ment. A nose clip was placed to assure no air leaks.The
valve expiratory port was connected to a Collins Multi-
modular Lung Analyzer (model 02303) in order to regis-
ter the respiratory pattern and tidal volume with a
graphic ink system.End-tidal carbon dioxide tension (PET-
CO2) was measured with a CO2 analyzer through a port
in the expiratory limb.The same equipment is ¢ttedwith
a pulse oximeter that was connected to one ¢nger to
continuously monitor the arterial oxygen saturation
(DX 7100 ETCO2/SPO2 reader,Dixtal, SP). An adjustable
resistor device employed in respiratory muscle training
(Treshold IMTs, Healthscan, NJ) was connected to the
valve inspiratory limb in order to introduce variable re-
spiratory loads. The volunteers were asked to breath in
the systemwithout the resistor device (0 load) and with
loads 7,14 and 21cmH2O/l/s.The di¡erent loads were ap-
plied at random and in a blinded manner for the volun-
teers. The subjects breathed over a period of 2min at
each load and, at the end of the secondminute, their re-spiratory parameters were recorded and they were
asked to rate the degree of respiratory discomfort using
a visual analog scale (VAS) (8). The analogue scale con-
sisted of a vertical 100mm line with the number zero at
the bottom and the number 100 at the top. The volun-
teers were instructed to consider zero as the indication
of no respiratory sensation at all and100 a sensation that
was intolerable.
Statistical analysis: Data are reported as means and
standard error of the means (SEM). Comparisons of the
measurements obtained with prednisone and placebo
weremadeusing thepaired t-test orWilcoxonnon-para-
metric test. A P value o0.05, corrected for multiple
comparisons, was considered to be signi¢cant.
RESULTS
All the volunteers showed normal spirometric para-
meters.Pulmonary function datawere expressed asper-
centage of thepredictednormal values; FVC=94+1.7%,
FEV1 = 93+1.5%, FVC/FEV1 = 97+0.8%, and FEF25^
75%=91+1.3%. Eight volunteers received placebo on D-2
andprednisone on D-3, and the remaining eight subjects
took the drugs in an inverse order.Themean time inter-
val betweenD-2 andD-3was 4.4+0.7 days (range: 2^10
days).
The mean maximum voluntary apnoea time did not
di¡er between theprednisone andplacebo days (Placebo
= 96+11.8 s Prednisone = 105+12.2 s; Fig.1).
Overall, prednisone did not led to changes in tidal vo-
lume, exhaled carbon dioxide levels or arterial oxygen
saturation at any load, compared to placebo. Prednisone
intake led to increases in respiratory rate and minute
ventilation, but the only change that reached statistical











Placebo 12.9+1.14* 13.8+1.21 13.4+1.40 13.1+1.04
Prednisone 15.3+1.31 14.6+1.60 15.6+1.54 15.4+1.76
TV
(l)
Placebo 0.86+0.11 1.0+0.17 1.0+0.16 1.1+0.17
Prednisone 0.85+0.01 1.1+0.15 1.0+0.18 1.1+0.17
VE (l) Placebo 10.0+0.86 11.8+1.28 11.5+1.21 12.3+1.23
Prednisone 11.9+1.28 13.1+1.51 13.2+1.51 14.7+1.95
PETCO2
(kPa)
Placebo 4.71+0.18 4.57+0.21 4.04+0.21 4.40+0.23
Prednisone 4.53+0.23 4.44+0.22 4.39+0.24 4.23+0.23
SaO2
(%)
Placebo 97.5+0.16 97.6+0.15 97.8+0.14 97.8+0.13
Prednisone 97.5+0.20 97.7+0.18 97.8+0.16 97.7+0.14
Note:RR: respiratoryrate;TV: tidal volume;VE: minute ventilation;PETCO2: end tidal expiratory CO2.
Po0.05 bypaired t-testcomparingplaceboprednisone.
STEROIDSANDDYSPNOEASENSATION 513signi¢cance was the elevation in respiratory rate under
basal conditions (Table1).
The use of prednisone did not in£uence themean dys-
pnoea sensation induced by di¡erent inspiratory loads
either (Fig. 2).
DISCUSSION
Some drugs have been explored as a means of alleviating
dyspnoea in chronic respiratory conditions. Such medi-
cations could act presumably by altering perceptual sen-
sitivityor byexertingrespiratorydepressive e¡ects (3,4).
Examples of this type of agents are opiates and anxioly-
tics. In addition, there are also suggestions that oral indo-
methacin and inhaled furosemide may positivelyFIG. 2. Mean dyspnoea sensations according to inspiratory
loads and type oftreatment.interfere with the mechanisms that give rise to breath-
lessness (9,10).
Corticosteroids are agents withmultiple physiological
e¡ects and of widespreaduse inmedicine, particularly in
the respiratory ¢eld (5). Recent investigations with the
use of positron emission tomography scans have showed
activation of speci¢c areas of thebrain in response todif-
ferent dyspnoea-inducing stimuli (11,12). It is well known
that steroids readily enter the central nervous system
and control gene expression in nervous cells via binding
to di¡erent intracellular receptors, which act as gene
transcription factors (13). In addition, several studies have
suggested that steroids produced locally in the brain, the
so-calledneurosteroids, mayregulate neuronal excitabil-
ity andmay in£uencephysiologic phenomena such as sex-
ual function, memory and response to stress (14).
However, until recently there were no studies speci¢-
cally designed to evaluate a possible role for steroids in
dyspnoea perception.
In a recent paper, Noseda et al. found that the admin-
istration of an IV bolus of 125mg of methylprednisolone
to 18 patients with asthma exacerbation did not reduce
dyspnoea more than saline solutionwithin a time course
of 60min (15).However, the period of1hmaybe not long
enough for a complete action of the drug on the CNS or
on receptors potentialy involved in respiratory percep-
tion located in the airways mucosa. In addition, due to
their strong anti-in£ammatory actions, the best way to
investigate a potential anti-dyspnoea role for steroids
some hours after their ingestion would be to induce un-
pleasant respiratory sensations in healthy volunteers
with no known pulmonary diseases.
There are several potential methods to induce dys-
pnoea in experimental conditions including performing
514 RESPIRATORYMEDICINEexercises, breathing hypercapnic gas mixtures, or the
application of ventilatory restrains (16). Previous papers
have employed normal volunteers breathing in respira-
tory circuitswith loads, andmeasurementofbreathhold-
ing times asmethods to investigate physiological aspects
and potential drug treatments for dyspnoea (9,12,16).
Using the latter instruments Nishino et al. were able to
demonstrate remarkable prolongations of the breath-
holding time and the period of no respiratory sensation
after inhalation of furosemide (9). These authors also
showed a decrease in the degree of respiratory discom-
fort associated with breathing with inspiratory loads
after furosemide inhalation in comparison to placebo.
We employed similar methods for practical reasons.
Furthermore, we could also investigate the steroid ef-
fects on dyspnoea generated by distinctmechanisms.
In the present investigation, the oral administration of
40mg of prednisone 6h before the studies did not signif-
icantly improve the breathholding time or the degree of
respiratory discomfort induced by di¡erent inspiratory
loads in a group of 16 healthy young volunteers, nor did
it lead to important changes in respiratory physiological
parameters. Prednisone intake was only associated with
a statistically signi¢cant increase in minute ventilation
during breathing in the circuit with no inspiratory loads.
Considering that increases inventilation aregenerally re-
lated toworsening in dyspnoea, this ¢ndingmaybe inter-
preted as further evidence against a bene¢cial e¡ect of
steroids on respiratory sensations.
In daily clinical practice, we have observed some pa-
tients with stable advanced COPD who are not able to
taper o¡ oral steroids due to worsening respiratory
symptoms. Sometimes subjects with end-stage pulmon-
ary ¢brotic disorders also report less dyspnoea and im-
provement inwell-being after a short trial of prednisone
ormethylprednisolone. In both situations, the subjective
amelioration of symptoms is not correlated with pul-
monary function or arterial blood gas improvements.
Based on the present results, we believe that these re-
ports may probably be the expression of a non-speci¢c
action of steroids on the CNS leading tomood elevation
and euphoria despite unchanged dyspnoea perception
andpulmonary status (5).However, it isworth to empha-
size that this study did not evaluate the chronic or the
multidose e¡ects of steroids on dyspnoea sensation.
The administration of prednisone on higher doses or for
longer periods of time might have yielded di¡erent re-
sults.
In conclusion, although steroidsmay certainly improve
respiratory conditions due to their anti-in£ammatory
actions, doctors should be aware that the available evi-dence does not support any speci¢c bene¢cial e¡ect of
these drugs on the perception of dyspnoea itself.
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